The current kidney transplant waitlistingcriterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual’s risk of progressing to kidney failure…. read more.
Weaning patients with acute kidney injury (AKI) from dialysis while they are still hospitalized may save them from remaining on the treatment for the rest of their lives,… read more.
Roche announced that the FDA has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as… read more.
Akebia Therapeutics®, Inc., announced that it will present data at the American Society of Nephrology Kidney Week 2025 (ASN Kidney Week), which will take place in Houston, TX from November 5-9, 2025. ASN… read more.
Novartis announced positive final results from APPLAUSE-IgAN, a Phase III study evaluating Fabhalta (iptacopan) in adults living with IgA nephropathy (IgAN). Fabhalta, an oral alternative complement pathway inhibitor,… read more.
Scientists have uncovered how lymphatic vessels – the kidney’s ‘plumbing system’ – undergo dramatic changes during chronic transplant rejection, becoming structurally disorganised and spreading to unusual parts of… read more.
Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and… read more.
Travere Therapeutics, Inc., announced that the FDA has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Filspari (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for… read more.
A molecule made by bacteria in the gut can hitch a ride to the kidneys, where it sets off a chain reaction of inflammation, scarring and fibrosis —… read more.
Researchers at the University of Pittsburgh have identified a new way of predicting whether a kidney donor and recipient are a good match for transplantation. The findings, published today in Science… read more.
Aurinia Pharmaceuticals Inc. announced that a post-hoc analysis of the 52-week, Phase III AURORA 1 study presented at at LUPUS 2025, the 16th International Congress on SLE, showed… read more.
Sobi will have a strong scientific presence at this year’s ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
